Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Eli Lilly is increasing Mounjaro's UK price by 170% to match European market levels, with the highest dose now costing £330.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

FDA grants full approval to Papzimeos for recurrent respiratory papillomatosis (RRP): Papzimeos becomes the first and only approved therapy for adults with RRP, targeting the root cause of the disease ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing ...